Global diabetic neuropathy market Size study, by Disorder Type (autonomic Neuropathy, peripheral Neuropathy, proximal neuropathy and focal Neuropathy) Treatment (drugs, physiotherapy, radiotherapy and others) Distribution Channel (clinics, hospitals and pharmacy) and Regional Forecasts 2018-2025

  • Product Code:
    RP-ID-10076462
  • Published Date:
    17 Jul 2021
  • Region:
    Global
  • Pages:
    200
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-14

Impact Analysis on the Growth of Market

Inflation and looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

..

..

The Research Report is Updated with 2021 Base Year, 2022 Estimated year and Forecast till 2031 with Market Insights.


With the dip in global production, the GDP has contracted in 2020 and impacted the market across the world. Upon placing a Sample Request, you will receive an updated report with 2021 as base year, 2022 as estimated year and forecast to 2031. This will have market drivers, recovery rate in the market, insights and competitive analysis.



Market Overview:

Translate Report

Global diabetic neuropathy market to reach USD 5.8 billion by 2025.

Global diabetic neuropathy market is valued approximately USD 3.8 billion in 2017 and is anticipated to grow with a healthy growth rate of more than 5.4 % over the forecast period 2018-2025. Key trends in the market is advent of new therapeutics for treatment of neuropathy and favorable reimbursement scenario which is expected to foster the growth of the diabetic neuropathy market. For instance: In 2016 as per the University of Cambridge, researchers have led to the development of a new approach to treatment of neuropathic pain. Further, the project focuses on a novel way of indirectly modulating the effect of the TRPV1, a significant initiator of the sensation of pain. Additionally, the team worked to show the effectiveness of using certain peptides to interface with the function of TRPV1 with an aim to eliminate neuropathic pain. As a result, healthcare institutions would be capable to deliver new therapeutics for treatment of neuropathy.
Key driving factors for the diabetic neuropathy market are rising prevalence of diabetes coupled with the changing lifestyles that results in to unhealthy dietary habits and patterns. According the Health Metrics - American Heart Association, in 2010 the prevalence of diabetes for adults was recorded to be 6.4% globally. This is expected to increase and reach up to 7.7% by the end of 2030, across the globe. Similarly, as per the MRC United Kingdom 2015, the estimated diabetes prevalence for adults between age group of 20-79 worldwide was around 387 million in 2014 which is estimated to reach around 592 million people by 2023. As a result, people suffering from diabetes are prone to nerve damages which are expected to boost the growth of the diabetic neuropathy market during 2018-2025. Furthermore, rise in demand for better neuropathy drugs offer lucrative growth prospects for the diabetic neuropathy market across the globe. However, high cost associated with diabetic neuropathy along with the side effects of the drugs are expected to hinder the growth of the market during the forecast period.

On the basis of segmentation, the diabetic neuropathy market is segmented into disorder type, treatment and distribution channel. The disorder type segment of global Diabetic neuropathy market is classified into autonomic Neuropathy, peripheral neuropathy, proximal neuropathy and focal neuropathy of which proximal neuropathy dominates the market as it is the most commonly found disorder in type 2 diabetes. On the basis of treatment segment, the market is classified into drugs, physiotherapy, radiotherapy and others. The distribution channel segment is classified into clinics, hospitals and pharmacy.

The regional analysis of diabetic neuropathy market is considered for the key regions such as North America, Europe, Asia Pacific, Latin America and ROW. North America holds the leading position in diabetic neuropathy market owing to the increase in prevalence of diabetes, improved healthcare infrastructure along with the rise in research and development activities. Whereas, Asia-Pacific is expected to emerge as the fastest growing region in terms of market share. The growth of Asia-Pacific is witnessed owing to increase R&D activities for drug discovery along with increasing aging population. Also, improving healthcare infrastructure and services in rural areas is also expected to supplement the growth of Asia-Pacific over the forecast period.
The leading market players include-

 Pfizer Inc.
 Janssen Pharmaceuticals, Inc.
 Eli Lilly and Company
 Cephalon, Inc.
 ACTAVIS
 GlaxoSmithKline
 MEDA Pharma GmbH & Co. KG
 NeuroMetrix, Inc
 Abbott Laboratories
 Lupin Limited

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Disorder Type
 Autonomic Neuropathy
 Peripheral Neuropathy
 Proximal Neuropathy
 Focal Neuropathy
By Treatment:
 Drugs
 Physiotherapy
 Radiotherapy
 Others
By Distribution Channel:
 Clinics
 Hospitals
 Pharmacy
By Regions:
 North America
o U.S.
o Canada
 Europe
o UK
o Germany
o ROE
 Asia Pacific
o China
o India
o Japan
o ROAPEC
 LAMEA
o Brazil
o Mexico
 ROW
o Middle East & Africa

Furthermore, years considered for the study are as follows:

Historical year – 2015, 2016
Base year – 2017
Forecast period – 2018 to 2025

Target Audience of the Global Diabetic neuropathy Market in Market Study:

 Key Consulting Companies & Advisors
 Large, medium-sized, and small enterprises
 Venture capitalists
 Value-Added Resellers (VARs)
 Third-party knowledge providers
 Investment bankers
 Investors


Geography Analysis:


The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

  • North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys  & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook

.

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Pfizer Inc.
Janssen Pharmaceuticals, Inc.
Eli Lilly and Company
Cephalon, Inc.
ACTAVIS
GlaxoSmithKline
MEDA Pharma GmbH & Co. KG
NeuroMetrix, Inc
Abbott Laboratories
Lupin Limited
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports